Market Overview:
The global intravenous (IV) iron drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of anemia, rising geriatric population, and growing demand for better treatment options. Based on type, the low molecular weight iron dextran segment is expected to account for the largest share of the global IV iron drugs market in 2018. This segment is also projected to grow at a higher CAGR than other segments during the forecast period. Factors such as its high efficacy and safety profile are driving its growth in this market. Based on application, hospitals are expected to account for the largest share of the global IV iron drugs market in 2018.
 Iron Drugs Industry Outlook.svg)
Product Definition:
Intraveno(IV) Iron Drugs are used to prevent or treat iron deficiency.
Low Molecular Weight Iron Dextran:
Low molecular weight iron dextran (LMWID) is a type of IV iron preparation that consists of non-cariogenic substances. It has been used as an alternative to regular IV ferrous sulfate in the treatment of anemia caused by chronic diseases such as cancer, and chronic infections. LMWID is also used in patients suffering from hemophilia A and B, where regular IV ferrous sulfate are ineffective.
Ferric Gluconate:
Ferric gluconate is a salt that contains iron, manganese, and gluconic acid. It is usually given with the drug to be administered intravenously. The most common drugs in which ferric gluconate is used are desferoxamine (DFO), hematinically extracted from deferoxamine mesylate (DMP) and other hematinic agents such as leukine, aranespogen, etc.
Application Insights:
The global intraveno(IV) iron drugs market is categorized based on application into hospitals, ambulatory surgical centers, and diagnostic centers. The hospital segment dominated the overall market in terms of revenue in 2017 owing to a high prevalence of chronic diseases such as anemia, thalassemia and others that require IV iron therapy for their treatment. Moreover, increasing awareness about these therapies among patients is also expected to drive growth during the forecast period.
The Ambulatory Surgical Center (ASC) segment is anticipated to grow at a lucrative rate over the forecast period due to growing demand for cost-effective healthcare services by individuals across developing countries such as India and China. In addition, initiatives undertaken by organizations including Iron Disorders Institute (IDI), World Health Organization (WHO) are aimed at improving access to IV iron drugs in ASCs across various regions which will further boost industry growth during the study period.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of patients suffering from iron deficiency anemia. The prevalence rate for this condition is high in this region as compared to other regions due to increased consumption of red meat and poultry, which leads to excessive loss of iron through feces. In addition, higher adoption rate for new intravenous (IV) drugs may also be attributed to its dominance over the forecast period.
Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing with increasing healthcare expenditure and rising patient awareness about available treatment options for various diseases across emerging countries such as China, India, South Korea & Japan etc.
Growth Factors:
- Increasing prevalence of anemia: The increasing prevalence of anemia is one of the key growth drivers for the intravenous iron drugs market. According to a study by the World Health Organization (WHO), nearly 1.62 billion people were affected by anemia in 2013, and this number is expected to increase to 1.85 billion by 2025. This growing population base is likely to drive demand for intravenous iron drugs in the coming years.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to create significant demand for intravenous iron drugs in the near future. Aged individuals are more susceptible to develop anemia due to various factors such as reduced intake of food, chronic diseases, etc., which makes them prime candidates for treatment with intravenous iron drugs therapies..
- Vifor Pharma announced positive results from its Phase III clinical trial evaluating
Scope Of The Report
Report Attributes
Report Details
Report Title
Intraveno(IV) Iron Drugs Market Research Report
By Type
Low Molecular Weight Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxyl Maltose
By Application
Hospitals, Ambulatory Surgical Centers, Diagnostic Centers
By Companies
Allergan, AMAG Pharmaceuticals, Galenica, Actavis, American Regent, Sanofi, Luitpold Pharmaceuticals, Fresenius Medical Care, Pharmacosmos, Vifor Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Intraveno(IV) Iron Drugs Market Report Segments:
The global Intraveno(IV) Iron Drugs market is segmented on the basis of:
Types
Low Molecular Weight Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxyl Maltose
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Diagnostic Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- AMAG Pharmaceuticals
- Galenica
- Actavis
- American Regent
- Sanofi
- Luitpold Pharmaceuticals
- Fresenius Medical Care
- Pharmacosmos
- Vifor Pharma
 Iron Drugs Market Overview.svg)
Highlights of The Intraveno(IV) Iron Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Low Molecular Weight Iron Dextran
- Ferric Gluconate
- Iron Sucrose
- Ferric Carboxyl Maltose
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Intraveno(IV) Iron Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Iron Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Intravenous iron drugs are medications that are given through a vein. These medications help to increase the amount of iron in the blood. Iron is important for carrying oxygen throughout the body and helping to create new red blood cells.
Some of the major players in the intraveno(iv) iron drugs market are Allergan, AMAG Pharmaceuticals, Galenica, Actavis, American Regent, Sanofi, Luitpold Pharmaceuticals, Fresenius Medical Care, Pharmacosmos, Vifor Pharma.
The intraveno(iv) iron drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Intraveno(IV) Iron Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Intraveno(IV) Iron Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Intraveno(IV) Iron Drugs Market - Supply Chain
4.5. Global Intraveno(IV) Iron Drugs Market Forecast
4.5.1. Intraveno(IV) Iron Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Intraveno(IV) Iron Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Intraveno(IV) Iron Drugs Market Absolute $ Opportunity
5. Global Intraveno(IV) Iron Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Type
5.3.1. Low Molecular Weight Iron Dextran
5.3.2. Ferric Gluconate
5.3.3. Iron Sucrose
5.3.4. Ferric Carboxyl Maltose
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Intraveno(IV) Iron Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centers
6.3.3. Diagnostic Centers
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Intraveno(IV) Iron Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Intraveno(IV) Iron Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Intraveno(IV) Iron Drugs Demand Share Forecast, 2019-2026
9. North America Intraveno(IV) Iron Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Diagnostic Centers
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Type
9.7.1. Low Molecular Weight Iron Dextran
9.7.2. Ferric Gluconate
9.7.3. Iron Sucrose
9.7.4. Ferric Carboxyl Maltose
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Intraveno(IV) Iron Drugs Demand Share Forecast, 2019-2026
10. Latin America Intraveno(IV) Iron Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Diagnostic Centers
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Type
10.7.1. Low Molecular Weight Iron Dextran
10.7.2. Ferric Gluconate
10.7.3. Iron Sucrose
10.7.4. Ferric Carboxyl Maltose
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Intraveno(IV) Iron Drugs Demand Share Forecast, 2019-2026
11. Europe Intraveno(IV) Iron Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Diagnostic Centers
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Type
11.7.1. Low Molecular Weight Iron Dextran
11.7.2. Ferric Gluconate
11.7.3. Iron Sucrose
11.7.4. Ferric Carboxyl Maltose
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Intraveno(IV) Iron Drugs Demand Share, 2019-2026
12. Asia Pacific Intraveno(IV) Iron Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Diagnostic Centers
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Type
12.7.1. Low Molecular Weight Iron Dextran
12.7.2. Ferric Gluconate
12.7.3. Iron Sucrose
12.7.4. Ferric Carboxyl Maltose
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Intraveno(IV) Iron Drugs Demand Share, 2019-2026
13. Middle East & Africa Intraveno(IV) Iron Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Diagnostic Centers
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Intraveno(IV) Iron Drugs Market Size and Volume Forecast by Type
13.7.1. Low Molecular Weight Iron Dextran
13.7.2. Ferric Gluconate
13.7.3. Iron Sucrose
13.7.4. Ferric Carboxyl Maltose
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Intraveno(IV) Iron Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Intraveno(IV) Iron Drugs Market: Market Share Analysis
14.2. Intraveno(IV) Iron Drugs Distributors and Customers
14.3. Intraveno(IV) Iron Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AMAG Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Galenica
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Actavis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. American Regent
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Luitpold Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Fresenius Medical Care
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pharmacosmos
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Vifor Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
